- Salvat is one of the top-rated pharmaceutical companies that has achieved the best rating in the PROFARMA program, among the 49 evaluated by the Ministry of Industry, Trade and Tourism.
- The PROFARMA Plan seeks to increase the competitiveness of the industry through the modernization of the sector and the enhancement of activities that provide greater added value.
- The company has won the award thanks to the continuous research and development of innovative medicines with high added value in ophthalmology, otology and in the treatment of bone fractures.
Salvat, an international pharmaceutical company focused on the development, manufacturing and commercialization through partners worldwide of products such as Otovel, Cetraxal, Monolitum Flas, Relive, Tebarat and Cristalmina, has obtained the rating of “Excellent” by the Technical Committee of the Program for the Promotion of Competitiveness in the Pharmaceutical Industry (PROFARMA), which has evaluated 49 applications from pharmaceutical companies.
The program, managed by the Ministry of Industry, Trade and Tourism, classifies pharmaceutical firms into groups and categories according to their excellence in various industrial, economic and research, development and innovation fields. In relation to their standards, the 49 applicant firms have been rated as “Excellent”, “Very Good”, “Good”, or “Acceptable”.
The main objective of the PROFARMA plan is to promote the competitiveness of the pharmaceutical industry in Spain, either by promoting activities that provide greater added value or by promoting R&D through investment in new facilities and technologies.
“This mention is a reflection of the firm commitment we have made to R&D in the different fields we explore, such as otolaryngology, ophthalmology or bone fractures, and reinforces our leadership position in these therapeutic areas”, explains Alberto Bueno, CEO of Salvat.
Innovative actor in different branches of medicine
Research and innovation are in the DNA of the company, which has made relevant contributions in the therapeutic advancement of various pathologies. In the field of ophthalmology, in addition to the development of an innovative ocular corticosteroid to treat inflammation and pain after cataract surgery, Salvat is working on four more projects such as glaucoma, dry eye, diabetic retinopathy and blepharitis.
The pharmaceutical company is also positioned as the number 1 company in the development of treatments for otology after the development of the first drug with specific indication for otomycosis. Additionally, Salvat has been working on a pioneering project based on pre-differentiated mesenchymal stem cells aimed at treating patients with bone consolidation problems after a fracture (atrophic pseudoarthrosis).
All these contributions have earned Salvat the recognition of the Technical Committee of the Program for the Promotion of Competitiveness in the Pharmaceutical Industry in this last call.